|
|
|
|
|
Last Trade
|
Last Trade:
$4.29
|
Change:
0.03 (0.70%)
|
Trade Time:
Apr 18
|
Market Cap:
$275.75M
|
|
|
|
|
|
|
Description of Business
|
|
Assertio Therapeutics, Inc. (Assertio or the Company) is a specialty
pharmaceutical company focused on neurology, orphan and specialty medicines. Our
current specialty pharmaceutical business includes the following three products
which we market in the United States (U.S.):
* Gralise® (gabapentin), a once daily product for the management of
postherpetic neuralgia (PHN), that we launched in October 2011.
* CAMBIA® (diclofenac potassium for oral solution), a non-steroidal
anti-inflammatory drug for the acute treatment of migraine attacks, that
we acquired in December 2013.
* Zipsor® (diclofenac potassium liquid filled capsules), a non-steroidal
anti-inflammatory drug for the treatment of mild to moderate acute pain,
that we acquired in June 2012.
|
|
|
|